SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.

Related Posts

How did hiring in the pharma industry perform in Q3 2023?

Oct 19, 2023

Congressmen: This Covid hearing ‘could have been an email’

Feb 1, 2024

Amgen in big data: theme innovation strategy

Mar 5, 2024